melatonin has been researched along with Fibrosis in 41 studies
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The PubMed, Cochrane Library, EMBASE, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang database, China Science and Technology Journal Database (VIP), and SinoMed databases were searched from inception to March 1st, 2022 to retrieve eligible studies that evaluated the effect of melatonin supplementation on the levels of malondialdehyde (MDA), lipid peroxidation (LPO), nitric oxide (NO), superoxide dismutase (SOD), glutathione (GSH), glutathione peroxidase (GPx), and catalase (CAT) in animal models of fibrosis." | 9.41 | Effect of melatonin on oxidative stress indicators in animal models of fibrosis: A systematic review and meta-analysis. ( Huang, XF; Li, D; Liao, YQ; Ling, YJ; Luo, JY; Pan, JH, 2023) |
| " To address this, we investigated the effect of melatonin on ischemia-induced fibrosis." | 7.96 | Melatonin suppresses ischemia-induced fibrosis by regulating miR-149. ( Han, YS; Lee, JH; Lee, SH, 2020) |
| "Melatonin can inhibit renal inflammation and fibrosis by inhibiting the NF-κB and TGF-β1/Smad3 signaling pathways, and melatonin may be a promising therapeutic target in diabetic nephropathy." | 7.96 | Melatonin Ameliorates Renal Fibrosis Through the Inhibition of NF-κB and TGF-β1/Smad3 Pathways in db/db Diabetic Mice. ( Fan, Z; Qi, X; Wu, Y; Xia, L; Yang, W, 2020) |
| "Melatonin is a hormone produced by the pineal gland, and it has extensive beneficial effects on various tissue and organs; however, whether melatonin has any effect on cardiac fibrosis in the pathogenesis of diabetic cardiomyopathy (DCM) is still unknown." | 7.96 | Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1/miR-141-mediated NLRP3 inflammasome and TGF-β1/Smads signaling in diabetic cardiomyopathy. ( Che, H; Dong, R; Li, H; Li, Y; Liu, Y; Lv, J; Sahil, A; Wang, L; Wang, Y; Xue, H; Yang, Z, 2020) |
| "To evaluate the melatonin effects in these animals, we studied the renal cytoarchitecture by means of morphological analyses, immunofluorescence expression of specific markers related to fibrosis, oxidative stress, inflammation and apoptosis." | 7.88 | Oral supplementation of melatonin protects against lupus nephritis renal injury in a pristane-induced lupus mouse model. ( Bonomini, F; Dos Santos, M; Favero, G; Rezzani, R; Rodella, LF; Stacchiotti, A; Veronese, FV, 2018) |
| "Melatonin, a circadian molecule secreted by the pineal gland, confers a protective role against cardiac hypertrophy induced by hyperthyroidism, chronic hypoxia, and isoproterenol." | 7.85 | Melatonin protects against the pathological cardiac hypertrophy induced by transverse aortic constriction through activating PGC-1β: In vivo and in vitro studies. ( Chen, X; Duan, W; Jin, Z; Jing, L; Li, B; Li, K; Liang, H; Liu, J; Liu, Z; Reiter, RJ; Ren, K; Yang, J; Yang, Y; Yi, D; Yi, W; Yu, B; Yu, S; Zhai, M; Zhang, B; Zhang, M, 2017) |
| "To investigate the effects of melatonin and octreotide in the prevention of peridural fibrosis in an experimental rat model." | 7.76 | Efects of melatonin and octreotide on peridural fibrosis in an animal model of laminectomy. ( Erol, FS; Ilhan, N; Kavakli, A; Ozercan, IH; Sarsilmaz, M, 2010) |
| "To investigate whether melatonin (MLT) treatment has any protective effect on unilateral ureteral obstruction (UUO)-induced kidney injury in rats." | 7.75 | Melatonin attenuates unilateral ureteral obstruction-induced renal injury by reducing oxidative stress, iNOS, MAPK, and NF-kB expression. ( Cekmen, M; Ilbey, YO; Ozbek, E; Ozbek, M; Simsek, A; Somay, A, 2009) |
| "The administration of L-NAME inhibited NOS activity, increased conjugated dienes concentration, elevated blood pressure and induced LVH and fibrosis (indicated by increased collagenous proteins and hydroxyproline levels)." | 7.75 | Melatonin prevents fibrosis but not hypertrophy development in the left ventricle of NG-nitro-L-arginine-methyl ester hypertensive rats. ( Adamcova, M; Barta, A; Krajcirovicova, K; Paulis, L; Pechanova, O; Pelouch, V; Simko, F; Zicha, J, 2009) |
| "We might hypothesize that the high rate of pseudarthrosis after spinal fusion for neurofibromatous scoliosis is related to two factors: the absence of neurofibromin and melatonin deficiency." | 7.71 | The role of neurofibromin and melatonin in pathogenesis of pseudarthrosis after spinal fusion for neurofibromatous scoliosis. ( Abdel-Wanis, ME; Kawahara, N, 2002) |
| "Heart failure is a multifactorial clinical syndrome characterized by the inability of the heart to pump sufficient blood to the body." | 6.58 | Melatonin in Heart Failure: A Promising Therapeutic Strategy? ( Maarman, GJ; Nduhirabandi, F, 2018) |
| "Fibrosis is a common occurrence following organ injury and failure." | 6.53 | Melatonin: the dawning of a treatment for fibrosis? ( Deng, C; Di, S; Fan, C; Hu, W; Jiang, S; Lv, J; Ma, Z; Reiter, RJ; Yan, X; Yang, Y, 2016) |
| "Melatonin has received attention as a potential antifibrotic agent due to its anti-proliferative actions on PSCs." | 5.72 | Melatonin modulates metabolic adaptation of pancreatic stellate cells subjected to hypoxia. ( Estaras, M; Garcia, A; Gonzalez, A; Iovanna, JL; Martinez, R; Ortiz-Placin, C; Santofimia-Castaño, P, 2022) |
| "The hypoxic microenvironment of cryptorchidism is an important factor in the impairment and fibrosis of Sertoli cells which result in blood-testis barrier (BTB) destruction and spermatogenesis loss." | 5.72 | Melatonin through blockade of Hif-1α signaling mediates the anti-fibrosis under hypoxia in canine Sertoli cells. ( Lee, Y; Li, D; Li, X; Wang, W; Wei, H; Wei, J; Xiao, L; Yao, H, 2022) |
| "Melatonin has been demonstrated to ameliorate cardiac hypertrophy and its accompanied fibrosis in previous studies." | 5.56 | A Peptide-Functionalized Magnetic Nanoplatform-Loaded Melatonin for Targeted Amelioration of Fibrosis in Pressure Overload-Induced Cardiac Hypertrophy. ( Cao, F; Lei, C; Liu, L; Wang, B; Wang, J; Wang, X; Yang, Q; Yuan, J; Zhang, J; Zhao, X; Zhu, X, 2020) |
| "Melatonin treatment for 8 weeks markedly attenuated cardiac hypertrophy and restored impaired cardiac function, as indicated by a decreased HW/BW ratio, reduced cell cross-sectional area and fibrosis, downregulated the mRNA levels of ANP, BNP, and β-MHC and ameliorated adverse effects on the LVEF and LVFS." | 5.56 | Melatonin ameliorates pressure overload-induced cardiac hypertrophy by attenuating Atg5-dependent autophagy and activating the Akt/mTOR pathway. ( Ding, P; Fan, ZG; Gao, EH; Kong, LH; Liu, Y; Xu, CN; Yang, J; Yang, LF, 2020) |
| "The PubMed, Cochrane Library, EMBASE, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang database, China Science and Technology Journal Database (VIP), and SinoMed databases were searched from inception to March 1st, 2022 to retrieve eligible studies that evaluated the effect of melatonin supplementation on the levels of malondialdehyde (MDA), lipid peroxidation (LPO), nitric oxide (NO), superoxide dismutase (SOD), glutathione (GSH), glutathione peroxidase (GPx), and catalase (CAT) in animal models of fibrosis." | 5.41 | Effect of melatonin on oxidative stress indicators in animal models of fibrosis: A systematic review and meta-analysis. ( Huang, XF; Li, D; Liao, YQ; Ling, YJ; Luo, JY; Pan, JH, 2023) |
| " Melatonin, an endogenous hormone, can alleviate fibrosis in multiple models of diseases." | 4.84 | Melatonin inhibits fibroblast cell functions and hypertrophic scar formation by enhancing autophagy through the MT2 receptor-inhibited PI3K/Akt /mTOR signaling. ( Cao, X; Chen, C; Chen, M; Deng, W; Dong, Y; Hu, Z; Huang, J; Long, Q; Luo, S; Lv, D; Rong, Y; Tang, B; Wang, H; Xu, Z, 2024) |
| "Melatonin is a hormone produced by the pineal gland, and it has extensive beneficial effects on various tissue and organs; however, whether melatonin has any effect on cardiac fibrosis in the pathogenesis of diabetic cardiomyopathy (DCM) is still unknown." | 3.96 | Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1/miR-141-mediated NLRP3 inflammasome and TGF-β1/Smads signaling in diabetic cardiomyopathy. ( Che, H; Dong, R; Li, H; Li, Y; Liu, Y; Lv, J; Sahil, A; Wang, L; Wang, Y; Xue, H; Yang, Z, 2020) |
| " To address this, we investigated the effect of melatonin on ischemia-induced fibrosis." | 3.96 | Melatonin suppresses ischemia-induced fibrosis by regulating miR-149. ( Han, YS; Lee, JH; Lee, SH, 2020) |
| "Melatonin can inhibit renal inflammation and fibrosis by inhibiting the NF-κB and TGF-β1/Smad3 signaling pathways, and melatonin may be a promising therapeutic target in diabetic nephropathy." | 3.96 | Melatonin Ameliorates Renal Fibrosis Through the Inhibition of NF-κB and TGF-β1/Smad3 Pathways in db/db Diabetic Mice. ( Fan, Z; Qi, X; Wu, Y; Xia, L; Yang, W, 2020) |
| "To evaluate the melatonin effects in these animals, we studied the renal cytoarchitecture by means of morphological analyses, immunofluorescence expression of specific markers related to fibrosis, oxidative stress, inflammation and apoptosis." | 3.88 | Oral supplementation of melatonin protects against lupus nephritis renal injury in a pristane-induced lupus mouse model. ( Bonomini, F; Dos Santos, M; Favero, G; Rezzani, R; Rodella, LF; Stacchiotti, A; Veronese, FV, 2018) |
| "Melatonin, a circadian molecule secreted by the pineal gland, confers a protective role against cardiac hypertrophy induced by hyperthyroidism, chronic hypoxia, and isoproterenol." | 3.85 | Melatonin protects against the pathological cardiac hypertrophy induced by transverse aortic constriction through activating PGC-1β: In vivo and in vitro studies. ( Chen, X; Duan, W; Jin, Z; Jing, L; Li, B; Li, K; Liang, H; Liu, J; Liu, Z; Reiter, RJ; Ren, K; Yang, J; Yang, Y; Yi, D; Yi, W; Yu, B; Yu, S; Zhai, M; Zhang, B; Zhang, M, 2017) |
| " Myocyte necrosis and fibrosis were diminished with melatonin while vasculitis was prevented." | 3.80 | Histopathological evaluation of melatonin as a protective agent in heart injury induced by radiation in a rat model. ( Erkal, HŞ; Gürses, I; Özeren, M; Serin, M; Yücel, N, 2014) |
| "To investigate the effects of melatonin and octreotide in the prevention of peridural fibrosis in an experimental rat model." | 3.76 | Efects of melatonin and octreotide on peridural fibrosis in an animal model of laminectomy. ( Erol, FS; Ilhan, N; Kavakli, A; Ozercan, IH; Sarsilmaz, M, 2010) |
| "To investigate whether melatonin (MLT) treatment has any protective effect on unilateral ureteral obstruction (UUO)-induced kidney injury in rats." | 3.75 | Melatonin attenuates unilateral ureteral obstruction-induced renal injury by reducing oxidative stress, iNOS, MAPK, and NF-kB expression. ( Cekmen, M; Ilbey, YO; Ozbek, E; Ozbek, M; Simsek, A; Somay, A, 2009) |
| "The administration of L-NAME inhibited NOS activity, increased conjugated dienes concentration, elevated blood pressure and induced LVH and fibrosis (indicated by increased collagenous proteins and hydroxyproline levels)." | 3.75 | Melatonin prevents fibrosis but not hypertrophy development in the left ventricle of NG-nitro-L-arginine-methyl ester hypertensive rats. ( Adamcova, M; Barta, A; Krajcirovicova, K; Paulis, L; Pechanova, O; Pelouch, V; Simko, F; Zicha, J, 2009) |
| " Melatonin, even at low dose, is an efficient agent in reducing negative parameters of cholestasis." | 3.73 | Protective effect of low dose of melatonin against cholestatic oxidative stress after common bile duct ligation in rats. ( Emre, MH; Esrefoglu, M; Gül, M; Polat, A; Selimoglu, MA, 2005) |
| " The effects of 900 MHz of radiation on fibrosis, lipid peroxidation, and anti-oxidant enzymes and the ameliorating effects of melatonin (Mel) were evaluated in rat skin." | 3.72 | Oxidative stress-mediated skin damage in an experimental mobile phone model can be prevented by melatonin. ( Akturk, O; Altuntas, I; Ayata, A; Mollaoglu, H; Ozguner, F; Yilmaz, HR, 2004) |
| "We might hypothesize that the high rate of pseudarthrosis after spinal fusion for neurofibromatous scoliosis is related to two factors: the absence of neurofibromin and melatonin deficiency." | 3.71 | The role of neurofibromin and melatonin in pathogenesis of pseudarthrosis after spinal fusion for neurofibromatous scoliosis. ( Abdel-Wanis, ME; Kawahara, N, 2002) |
| "Heart failure is a multifactorial clinical syndrome characterized by the inability of the heart to pump sufficient blood to the body." | 2.58 | Melatonin in Heart Failure: A Promising Therapeutic Strategy? ( Maarman, GJ; Nduhirabandi, F, 2018) |
| "Fibrosis is a common occurrence following organ injury and failure." | 2.53 | Melatonin: the dawning of a treatment for fibrosis? ( Deng, C; Di, S; Fan, C; Hu, W; Jiang, S; Lv, J; Ma, Z; Reiter, RJ; Yan, X; Yang, Y, 2016) |
| "The hypoxic microenvironment of cryptorchidism is an important factor in the impairment and fibrosis of Sertoli cells which result in blood-testis barrier (BTB) destruction and spermatogenesis loss." | 1.72 | Melatonin through blockade of Hif-1α signaling mediates the anti-fibrosis under hypoxia in canine Sertoli cells. ( Lee, Y; Li, D; Li, X; Wang, W; Wei, H; Wei, J; Xiao, L; Yao, H, 2022) |
| "Melatonin has received attention as a potential antifibrotic agent due to its anti-proliferative actions on PSCs." | 1.72 | Melatonin modulates metabolic adaptation of pancreatic stellate cells subjected to hypoxia. ( Estaras, M; Garcia, A; Gonzalez, A; Iovanna, JL; Martinez, R; Ortiz-Placin, C; Santofimia-Castaño, P, 2022) |
| "Melatonin has been demonstrated to ameliorate cardiac hypertrophy and its accompanied fibrosis in previous studies." | 1.56 | A Peptide-Functionalized Magnetic Nanoplatform-Loaded Melatonin for Targeted Amelioration of Fibrosis in Pressure Overload-Induced Cardiac Hypertrophy. ( Cao, F; Lei, C; Liu, L; Wang, B; Wang, J; Wang, X; Yang, Q; Yuan, J; Zhang, J; Zhao, X; Zhu, X, 2020) |
| "Melatonin treatment for 8 weeks markedly attenuated cardiac hypertrophy and restored impaired cardiac function, as indicated by a decreased HW/BW ratio, reduced cell cross-sectional area and fibrosis, downregulated the mRNA levels of ANP, BNP, and β-MHC and ameliorated adverse effects on the LVEF and LVFS." | 1.56 | Melatonin ameliorates pressure overload-induced cardiac hypertrophy by attenuating Atg5-dependent autophagy and activating the Akt/mTOR pathway. ( Ding, P; Fan, ZG; Gao, EH; Kong, LH; Liu, Y; Xu, CN; Yang, J; Yang, LF, 2020) |
| "Melatonin-treated BDL rats received daily melatonin 100 mg/kg/day via intraperitoneal injection." | 1.40 | Melatonin attenuates oxidative stress, liver damage and hepatocyte apoptosis after bile-duct ligation in rats. ( Aktas, C; Erboga, M; Kanter, M; Mete, R; Oran, M, 2014) |
| "Melatonin (MEL) has been proposed as a therapeutic agent for the oral cavity, due to its antioxidant and anti-inflammatory effects since periodontal diseases are aggravated by free radicals, and by disproportionate immunological response to plaque microorganism." | 1.39 | Anti-fibrotic and anti-inflammatory properties of melatonin on human gingival fibroblasts in vitro. ( Gómez-Florit, M; Monjo, M; Ramis, JM, 2013) |
| "Melatonin treatment increased GSH levels and GSH-Px activity, decreased MDA level in testicular tissue, and increased plasma T level." | 1.35 | Potential chemoprotective effect of melatonin in cyclophosphamide- and cisplatin-induced testicular damage in rats. ( Cekmen, M; Ilbey, YO; Otunctemur, A; Ozbek, E; Simsek, A; Somay, A, 2009) |
| "In chronic pancreatitis and pancreatic cancer, progressive fibrosis with the accumulation of extracellular matrix occurs." | 1.35 | Pancreatic stellate/myofibroblast cells express G-protein-coupled melatonin receptor 1. ( Aust, S; Jäger, W; Kirschner, H; Klimpfinger, M; Thalhammer, T, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (19.51) | 29.6817 |
| 2010's | 14 (34.15) | 24.3611 |
| 2020's | 19 (46.34) | 2.80 |
| Authors | Studies |
|---|---|
| Estaras, M | 1 |
| Martinez, R | 1 |
| Garcia, A | 1 |
| Ortiz-Placin, C | 1 |
| Iovanna, JL | 1 |
| Santofimia-Castaño, P | 1 |
| Gonzalez, A | 1 |
| Wei, H | 1 |
| Xiao, L | 1 |
| Yao, H | 1 |
| Li, X | 1 |
| Wang, W | 1 |
| Lee, Y | 1 |
| Li, D | 2 |
| Wei, J | 1 |
| Jiang, W | 1 |
| Jin, L | 1 |
| Ju, D | 1 |
| Lu, Z | 1 |
| Wang, C | 1 |
| Guo, X | 1 |
| Zhao, H | 1 |
| Shen, S | 1 |
| Cheng, Z | 1 |
| Shen, J | 1 |
| Zong, G | 1 |
| Chen, J | 1 |
| Li, K | 2 |
| Yang, L | 2 |
| Zhang, Z | 1 |
| Feng, Y | 1 |
| Shen, JZ | 1 |
| Zhang, EE | 1 |
| Wan, R | 1 |
| Pan, JH | 1 |
| Huang, XF | 1 |
| Liao, YQ | 1 |
| Ling, YJ | 1 |
| Luo, JY | 1 |
| Li, N | 3 |
| Xiong, R | 1 |
| Li, G | 1 |
| Wang, B | 2 |
| Geng, Q | 1 |
| Ziegler, KA | 1 |
| Ahles, A | 1 |
| Dueck, A | 1 |
| Esfandyari, D | 1 |
| Pichler, P | 1 |
| Weber, K | 1 |
| Kotschi, S | 1 |
| Bartelt, A | 1 |
| Sinicina, I | 1 |
| Graw, M | 1 |
| Leonhardt, H | 1 |
| Weckbach, LT | 1 |
| Massberg, S | 1 |
| Schifferer, M | 1 |
| Simons, M | 1 |
| Hoeher, L | 1 |
| Luo, J | 1 |
| Ertürk, A | 1 |
| Schiattarella, GG | 1 |
| Sassi, Y | 1 |
| Misgeld, T | 1 |
| Engelhardt, S | 1 |
| Dong, Y | 1 |
| Cao, X | 1 |
| Huang, J | 1 |
| Hu, Z | 1 |
| Chen, C | 1 |
| Chen, M | 1 |
| Long, Q | 1 |
| Xu, Z | 1 |
| Lv, D | 1 |
| Rong, Y | 1 |
| Luo, S | 1 |
| Wang, H | 2 |
| Deng, W | 1 |
| Tang, B | 1 |
| Yang, Z | 2 |
| He, Y | 1 |
| Ma, Q | 1 |
| Zhang, Q | 1 |
| Che, H | 1 |
| Wang, Y | 1 |
| Li, H | 1 |
| Li, Y | 1 |
| Sahil, A | 1 |
| Lv, J | 2 |
| Liu, Y | 2 |
| Dong, R | 1 |
| Xue, H | 1 |
| Wang, L | 1 |
| Han, YS | 2 |
| Lee, JH | 4 |
| Lee, SH | 4 |
| Zhao, X | 1 |
| Wang, X | 2 |
| Wang, J | 1 |
| Yuan, J | 1 |
| Zhang, J | 2 |
| Zhu, X | 1 |
| Lei, C | 1 |
| Yang, Q | 1 |
| Cao, F | 1 |
| Liu, L | 1 |
| Wang, Z | 1 |
| Gao, F | 1 |
| Lei, Y | 1 |
| Li, Z | 1 |
| Lu, L | 2 |
| Ma, J | 1 |
| Sun, M | 1 |
| Gao, E | 1 |
| Ren, J | 1 |
| Yang, J | 3 |
| Fan, Z | 1 |
| Qi, X | 1 |
| Yang, W | 1 |
| Xia, L | 1 |
| Wu, Y | 1 |
| Xu, CN | 1 |
| Kong, LH | 1 |
| Ding, P | 1 |
| Fan, ZG | 1 |
| Gao, EH | 1 |
| Yang, LF | 1 |
| Yoon, YM | 3 |
| Go, G | 3 |
| Yun, CW | 1 |
| Lim, JH | 2 |
| Jiang, J | 1 |
| Liang, S | 1 |
| Du, Z | 1 |
| Xu, Q | 1 |
| Duan, J | 1 |
| Sun, Z | 1 |
| Yoon, S | 1 |
| Lee, G | 1 |
| Wu, N | 1 |
| Meng, F | 2 |
| Zhou, T | 1 |
| Han, Y | 2 |
| Kennedy, L | 2 |
| Venter, J | 2 |
| Francis, H | 2 |
| DeMorrow, S | 2 |
| Onori, P | 2 |
| Invernizzi, P | 1 |
| Bernuzzi, F | 1 |
| Mancinelli, R | 2 |
| Gaudio, E | 2 |
| Franchitto, A | 2 |
| Glaser, S | 2 |
| Alpini, G | 2 |
| Zhai, M | 1 |
| Liu, Z | 1 |
| Zhang, B | 1 |
| Jing, L | 1 |
| Li, B | 1 |
| Chen, X | 1 |
| Zhang, M | 1 |
| Yu, B | 1 |
| Ren, K | 1 |
| Yang, Y | 2 |
| Yi, W | 1 |
| Liu, J | 1 |
| Yi, D | 1 |
| Liang, H | 1 |
| Jin, Z | 1 |
| Reiter, RJ | 2 |
| Duan, W | 1 |
| Yu, S | 1 |
| Simko, F | 3 |
| Pechanova, O | 2 |
| Repova, K | 1 |
| Aziriova, S | 1 |
| Krajcirovicova, K | 2 |
| Celec, P | 1 |
| Tothova, L | 1 |
| Vrankova, S | 1 |
| Balazova, L | 1 |
| Zorad, S | 1 |
| Adamcova, M | 2 |
| Dos Santos, M | 1 |
| Favero, G | 1 |
| Bonomini, F | 1 |
| Stacchiotti, A | 1 |
| Rodella, LF | 1 |
| Veronese, FV | 1 |
| Rezzani, R | 1 |
| Nduhirabandi, F | 1 |
| Maarman, GJ | 1 |
| Li, J | 1 |
| Yan, S | 1 |
| Lu, Y | 1 |
| Miao, X | 1 |
| Gu, Z | 1 |
| Shao, Y | 1 |
| Paulis, L | 2 |
| Gómez-Florit, M | 1 |
| Ramis, JM | 1 |
| Monjo, M | 1 |
| Ray, D | 1 |
| Greene, J | 1 |
| Renzi, A | 1 |
| Gürses, I | 1 |
| Özeren, M | 1 |
| Serin, M | 1 |
| Yücel, N | 1 |
| Erkal, HŞ | 1 |
| Hu, W | 1 |
| Ma, Z | 1 |
| Jiang, S | 1 |
| Fan, C | 1 |
| Deng, C | 1 |
| Yan, X | 1 |
| Di, S | 1 |
| Ranga Rao, S | 1 |
| Subbarayan, R | 1 |
| Ajitkumar, S | 1 |
| Murugan Girija, D | 1 |
| Ilbey, YO | 2 |
| Ozbek, E | 2 |
| Simsek, A | 2 |
| Otunctemur, A | 1 |
| Cekmen, M | 2 |
| Somay, A | 2 |
| Aust, S | 1 |
| Jäger, W | 1 |
| Kirschner, H | 1 |
| Klimpfinger, M | 1 |
| Thalhammer, T | 1 |
| Ozbek, M | 1 |
| Zicha, J | 1 |
| Barta, A | 1 |
| Pelouch, V | 1 |
| Erol, FS | 1 |
| Kavakli, A | 1 |
| Ilhan, N | 1 |
| Ozercan, IH | 1 |
| Sarsilmaz, M | 1 |
| Aktas, C | 1 |
| Kanter, M | 1 |
| Erboga, M | 1 |
| Mete, R | 1 |
| Oran, M | 1 |
| Mizrak, B | 1 |
| Parlakpinar, H | 1 |
| Acet, A | 1 |
| Turkoz, Y | 1 |
| Ayata, A | 1 |
| Mollaoglu, H | 1 |
| Yilmaz, HR | 1 |
| Akturk, O | 1 |
| Ozguner, F | 1 |
| Altuntas, I | 1 |
| Esrefoglu, M | 1 |
| Gül, M | 1 |
| Emre, MH | 1 |
| Polat, A | 1 |
| Selimoglu, MA | 1 |
| Abdel-Wanis, ME | 1 |
| Kawahara, N | 1 |
3 reviews available for melatonin and Fibrosis
| Article | Year |
|---|---|
Effect of melatonin on oxidative stress indicators in animal models of fibrosis: A systematic review and meta-analysis.
Topics: Animals; Antioxidants; Catalase; Fibrosis; Glutathione; Glutathione Peroxidase; Humans; Malondialdeh | 2023 |
Melatonin in Heart Failure: A Promising Therapeutic Strategy?
Topics: Animals; Fibrosis; Heart Failure; Humans; Hypertension; Melatonin | 2018 |
Melatonin: the dawning of a treatment for fibrosis?
Topics: Animals; Extracellular Matrix; Fibrosis; Heart Diseases; Humans; Kidney Diseases; Liver Cirrhosis; M | 2016 |
38 other studies available for melatonin and Fibrosis
| Article | Year |
|---|---|
Melatonin modulates metabolic adaptation of pancreatic stellate cells subjected to hypoxia.
Topics: Actins; Cells, Cultured; Collagen; Fibrosis; Humans; Hypoxia; Melatonin; Pancreas; Pancreatic Stella | 2022 |
Melatonin through blockade of Hif-1α signaling mediates the anti-fibrosis under hypoxia in canine Sertoli cells.
Topics: Acetylserotonin O-Methyltransferase; Animals; Cryptorchidism; Dogs; Fibrosis; Hypoxia; Hypoxia-Induc | 2022 |
The pancreatic clock is a key determinant of pancreatic fibrosis progression and exocrine dysfunction.
Topics: Animals; ARNTL Transcription Factors; Aryl Hydrocarbon Receptor Nuclear Translocator; Fibrosis; Inte | 2022 |
PM2.5 contributed to pulmonary epithelial senescence and ferroptosis by regulating USP3-SIRT3-P53 axis.
Topics: Animals; Cellular Senescence; Ferroptosis; Fibrosis; Lung; Lung Injury; Melatonin; Mice; Particulate | 2023 |
Immune-mediated denervation of the pineal gland underlies sleep disturbance in cardiac disease.
Topics: Animals; Circadian Rhythm; Fibrosis; Heart Diseases; Humans; Macrophages; Melatonin; Mice; Pineal Gl | 2023 |
Melatonin inhibits fibroblast cell functions and hypertrophic scar formation by enhancing autophagy through the MT2 receptor-inhibited PI3K/Akt /mTOR signaling.
Topics: Animals; Autophagy; Cicatrix, Hypertrophic; Fibroblasts; Fibrosis; Humans; Melatonin; Phosphatidylin | 2024 |
Alleviative effect of melatonin against the nephrotoxicity induced by cadmium exposure through regulating renal oxidative stress, inflammatory reaction, and fibrosis in a mouse model.
Topics: Animals; Cadmium; Drug-Related Side Effects and Adverse Reactions; Fibrosis; Humans; Inflammation; K | 2023 |
Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1/miR-141-mediated NLRP3 inflammasome and TGF-β1/Smads signaling in diabetic cardiomyopathy.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Fibrosis; Gene Ex | 2020 |
Melatonin suppresses ischemia-induced fibrosis by regulating miR-149.
Topics: Animals; Fibrosis; Inflammation; Ischemia; Melatonin; Mice; MicroRNAs; Myoblasts; Peroxisome Prolife | 2020 |
A Peptide-Functionalized Magnetic Nanoplatform-Loaded Melatonin for Targeted Amelioration of Fibrosis in Pressure Overload-Induced Cardiac Hypertrophy.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Drug Delivery Systems; Ferrosoferric Oxide; Fibrosis; | 2020 |
Melatonin ameliorates renal fibroblast-myofibroblast transdifferentiation and renal fibrosis through miR-21-5p regulation.
Topics: Actins; Animals; Biomarkers; Cell Survival; Cell Transdifferentiation; Disease Models, Animal; Disea | 2020 |
Melatonin Ameliorates MI-Induced Cardiac Remodeling and Apoptosis through a JNK/p53-Dependent Mechanism in Diabetes Mellitus.
Topics: Animals; Anisomycin; Apoptosis; Cell Hypoxia; Cell Line; Cytoprotection; Diabetes Mellitus, Experime | 2020 |
Melatonin Ameliorates Renal Fibrosis Through the Inhibition of NF-κB and TGF-β1/Smad3 Pathways in db/db Diabetic Mice.
Topics: Animals; Central Nervous System Depressants; Diabetes Mellitus, Experimental; Diabetic Nephropathies | 2020 |
Melatonin ameliorates pressure overload-induced cardiac hypertrophy by attenuating Atg5-dependent autophagy and activating the Akt/mTOR pathway.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein 5; Cardiomegaly; Disease Models, Animal; Fi | 2020 |
Melatonin Protects Human Renal Proximal Tubule Epithelial Cells Against High Glucose-Mediated Fibrosis via the Cellular Prion Protein-TGF-β-Smad Signaling Axis.
Topics: Blotting, Western; Catalase; Cell Proliferation; Collagen Type I; Fibronectins; Fibrosis; Glucose; H | 2020 |
Melatonin Suppresses Renal Cortical Fibrosis by Inhibiting Cytoskeleton Reorganization and Mitochondrial Dysfunction through Regulation of miR-4516.
Topics: Animals; Cell Line; Cytoskeleton; Fibrosis; Gene Expression Regulation; Kidney Cortex; Male; Melaton | 2020 |
Melatonin ameliorates PM
Topics: Acetylation; Animals; Antioxidants; Cardiomyopathies; Cardiotoxicity; Cell Line; Disease Models, Ani | 2021 |
Melatonin Treatment Improves Renal Fibrosis via miR-4516/SIAH3/PINK1 Axis.
Topics: Animals; Cell Line; Disease Models, Animal; Fibrosis; Humans; Kidney; Kidney Function Tests; Male; M | 2021 |
Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.
Topics: Angiogenesis Inducing Agents; Animals; Cell Proliferation; Cholangitis, Sclerosing; Darkness; Diseas | 2017 |
Melatonin protects against the pathological cardiac hypertrophy induced by transverse aortic constriction through activating PGC-1β: In vivo and in vitro studies.
Topics: Angiotensin II; Animals; Antioxidants; Cardiomegaly; Disease Models, Animal; Drug Evaluation, Precli | 2017 |
Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril.
Topics: Acetylcysteine; Animals; Antihypertensive Agents; Captopril; Disease Models, Animal; Fibrosis; Heart | 2017 |
Oral supplementation of melatonin protects against lupus nephritis renal injury in a pristane-induced lupus mouse model.
Topics: Animals; Apoptosis; Autoantibodies; Cytokines; Disease Models, Animal; Female; Fibrosis; Inflammatio | 2018 |
Melatonin attenuates renal fibrosis in diabetic mice by activating the AMPK/PGC1α signaling pathway and rescuing mitochondrial function.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Diabetes Mellitus, Experimental; Down-Regulation; | 2019 |
Antifibrotic effect of melatonin--perspective protection in hypertensive heart disease.
Topics: Animals; Cardiomegaly; Fibrosis; Humans; Hypertension; Melatonin; Myocardium | 2013 |
Anti-fibrotic and anti-inflammatory properties of melatonin on human gingival fibroblasts in vitro.
Topics: Anti-Inflammatory Agents; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Fibrosis; Gingiva; Humans; | 2013 |
Prolonged exposure of cholestatic rats to complete dark inhibits biliary hyperplasia and liver fibrosis.
Topics: Animals; ARNTL Transcription Factors; Arylalkylamine N-Acetyltransferase; Bile Acids and Salts; Bile | 2014 |
Histopathological evaluation of melatonin as a protective agent in heart injury induced by radiation in a rat model.
Topics: Animals; Cardiomyopathies; Coronary Artery Disease; Coronary Vessels; Cytoprotection; Fibrosis; Male | 2014 |
4PBA strongly attenuates endoplasmic reticulum stress, fibrosis, and mitochondrial apoptosis markers in cyclosporine treated human gingival fibroblasts.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Survival; Cells, Cultured; Cyclosporine; Cytoprotecti | 2018 |
Potential chemoprotective effect of melatonin in cyclophosphamide- and cisplatin-induced testicular damage in rats.
Topics: Animals; Antioxidants; Cisplatin; Cyclophosphamide; Fibrosis; Glutathione; Glutathione Peroxidase; I | 2009 |
Pancreatic stellate/myofibroblast cells express G-protein-coupled melatonin receptor 1.
Topics: Carcinoma, Pancreatic Ductal; Cell Division; Epithelial Cells; Fibrosis; Humans; Melatonin; Microsco | 2008 |
Melatonin attenuates unilateral ureteral obstruction-induced renal injury by reducing oxidative stress, iNOS, MAPK, and NF-kB expression.
Topics: Animals; Cell Movement; Fibrosis; Glutathione; Immunohistochemistry; Kidney Diseases; Leukocytes; Li | 2009 |
Melatonin prevents fibrosis but not hypertrophy development in the left ventricle of NG-nitro-L-arginine-methyl ester hypertensive rats.
Topics: Animals; Blood Pressure; Fibrosis; Free Radical Scavengers; Heart Ventricles; Hemodynamics; Hydroxyp | 2009 |
Efects of melatonin and octreotide on peridural fibrosis in an animal model of laminectomy.
Topics: Animals; Central Nervous System Depressants; Fibrosis; Laminectomy; Lumbar Vertebrae; Male; Melatoni | 2010 |
Melatonin attenuates oxidative stress, liver damage and hepatocyte apoptosis after bile-duct ligation in rats.
Topics: Animals; Apoptosis; Cell Proliferation; Cholestasis; Common Bile Duct; Fibrosis; Glutathione; Hepato | 2014 |
Effects of pinealectomy and exogenous melatonin on rat hearts.
Topics: Animals; Aorta; Cholesterol; Female; Fibrosis; Glutathione; Heart; Heart Valves; Malondialdehyde; Me | 2004 |
Oxidative stress-mediated skin damage in an experimental mobile phone model can be prevented by melatonin.
Topics: Animals; Antioxidants; Catalase; Cell Phone; Disease Models, Animal; Fibrosis; Free Radical Scavenge | 2004 |
Protective effect of low dose of melatonin against cholestatic oxidative stress after common bile duct ligation in rats.
Topics: Animals; Antioxidants; Cholestasis; Cholestasis, Extrahepatic; Common Bile Duct; Dose-Response Relat | 2005 |
The role of neurofibromin and melatonin in pathogenesis of pseudarthrosis after spinal fusion for neurofibromatous scoliosis.
Topics: Bone and Bones; Fibrosis; Humans; Melatonin; Models, Biological; Neurofibromatosis 1; Neurofibromin | 2002 |